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Abstract
Background—Implementation of the Affordable Care Act motivates assessment of health 
insurance and supplementary programs, such as the AIDS Drug Assistance Program (ADAP) on 
health outcomes of HIV-infected people in the United States. We assessed the effects of health 
insurance, ADAP, and income on HIV viral load suppression.
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Methods—We utilized existing cohort data from the HIV-infected participants of the Women’s 
Interagency HIV Study (WIHS). Cox proportional hazards models were used to estimate the time 
from 2006 to unsuppressed HIV viral load (>200 copies/mL) among those with Medicaid, private, 
Medicare or other public insurance, and no insurance, stratified by use of ADAP.
Results—In 2006, 65% of women had Medicaid, 18% had private insurance, 3% had Medicare 
or other public insurance, and 14% reported no health insurance. ADAP coverage was reported by 
284 women (20%); 56% of uninsured participants reported ADAP coverage. After accounting for 
study site, age, race, lowest observed CD4, and prior health insurance, the hazard ratio (HR) for 
unsuppressed viral load among those privately insured without ADAP, compared to those on 
Medicaid without ADAP (referent group), was 0.61 (95% CI: 0.48–0.77). Among the uninsured, 
those with ADAP had a lower relative hazard of unsuppressed viral load compared to the referent 
group (HR, 95% CI: 0.49, 0.28–0.85) than those without ADAP (HR, 95% CI: 1.00, 0.63–1.57).
Conclusions—While women with private insurance are most likely to be virally suppressed, 
ADAP also contributes to viral load suppression. Continued support of this program may be 
especially critical for states that have not expanded Medicaid.
Keywords
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INTRODUCTION
Health care availability, accessibility, and quality are important determinants of health.1 
About 15% of the US population lacked health insurance prior to the Affordable Care Act; 
Blacks and Hispanics, racial/ethnic groups that are disproportionately both poor and affected 
by HIV, were most likely to be uninsured.2 In 2009, among US adults in HIV care, 41% had 
Medicaid coverage, 30% were privately insured, 17% were uninsured, 6% had Medicare 
coverage, and 5% had other public coverage.3 In the same year, 40% of all HIV-infected 
people received services through the Ryan White HIV/AIDS program.3 This program is a 
federal program that disburses funds to states and localities for a variety of HIV related 
programs including HIV counseling and testing, engagement in care, health insurance 
premium assistance, medical transportation, and case management.4 The AIDS Drug 
Assistance Program (ADAP) is a part of the Ryan White program that provides HIV-related 
prescription drugs to low-income individuals with limited or no prescription drug coverage. 
Health insurance and prescription drug coverage increase use of antiretroviral therapy 
(ART),5–8 a lifesaving therapy for those with HIV infection. To better understand the effects 
of the expansion of services and health insurance coverage resulting from the Affordable 
Care Act, estimates of the effects of insurance prior to implementation are needed.
Suppression of plasma HIV viral load with ART has critical implications for the health of 
HIV-infected individuals and their ability to transmit infection.9,10 Consistent use of ART is 
necessary for HIV suppression; failure to establish or sustain viral suppression can result 
from poor adherence11 and interrupted access to medication.12 Given the high cost of HIV 
treatment in the US,13 financial resources and health insurance6,14 or ART provision through 
other means, such as ADAP, are crucial to maintaining uninterrupted access to ART, averting 
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disease progression and death, and limiting HIV transmission. While the link between health 
insurance and ART prescription6,8 and initiation7 has been established, to our knowledge 
there has been no research that bridges these intermediaries to study the effects of health 
insurance on viral load suppression.
We used prospective data from the Women’s Interagency HIV Study (WIHS) to estimate the 
effect of health insurance status and type on unsuppressed HIV viral load in the era of 
modern ART and to estimate the effect of income on unsuppressed HIV viral load among 
participants with Medicaid. We address both initial and ongoing access to ART by including 
those who have never received ART and those who are already on therapy. Because many 
states began enacting policy changes as early as 2010 in anticipation of the Affordable Care 
Act, we analyzed data from 2006 through 2009.
METHODS
Women’s Interagency HIV Study
Recruitment, retention, and study characteristics of WIHS participants have been previously 
reported.15,16 In brief, HIV-infected and -uninfected women were recruited to participate in 
this cohort study during four waves. For this analysis, we included HIV-infected women 
enrolled during 1994–5 and 2001–2 who had a viral load measurement at visit 24 (index 
date, April–September 2006) or at the subsequent visit, 6 months later. Study visits are 
conducted approximately every 6 months and consist of a structured interview, clinical 
examination, and specimen collection.
Ascertainment of Viral Load
Viral load was measured every 6 months using the Nuclisens HIV-1 QT assay, which has a 
lower limit of detection of 80 copies/mL and an upper limit of quantification of 3.47×106 
copies/mL. Unsuppressed viral load was defined as a single viral load measurement of >200 
copies/mL.17
Ascertainment of Health Insurance Status, Income, and Covariates
Insurance type at the index date was the primary exposure. We categorized the insured into 
four mutually exclusive groups using a classification hierarchy similar to the one used by the 
Kaiser Family Foundation.3 Insurance categories were assigned in this order: Medicaid or 
Medi-Cal, private insurance (including student insurance), other insurance (including 
Medicare, Tricare/CHAMPUS, Veteran’s Administration, and city or county coverage), and 
no health insurance. Participants also reported participation in ADAP for which eligibility 
depends on state of residence; insurance was stratified by ADAP participation.
Annual household income, self-reported at each visit, was a second exposure of interest. As 
most participants on Medicaid reported incomes in the lowest three categories (i.e., <$6,000, 
$6,001 to $12,000, $12,001 to $18,000), for select analyses we collapsed all individuals with 
incomes of >$18,000 per year into one category.
Birthdate, recruitment wave, and educational attainment (in categories of less than, equal to, 
or more than high school education) were collected at entry into the cohort. Race was 
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reported in the following categories: white and non-Hispanic, white and Hispanic, African 
American and non-Hispanic, African American and Hispanic, Other Hispanic, Asian/Pacific 
Islander, Native American/Alaskan, and Other. Given the small number of participants, we 
dichotomized race into African American and Other. We also created a variable for Hispanic 
ethnicity. At each visit, participants reported diagnoses of AIDS since the last visit. CD4+ T 
cell counts were measured at each visit; the nadir, or lowest observed value prior to index 
date, was used as a proxy for HIV disease progression.
Statistical Methods
Time was counted from the index date until the first observed unsuppressed viral load (>200 
copies/mL) or censoring (death or loss to follow up (> 3 consecutive missed visits)). Time 
was administratively censored after 3 years. Hazard ratios were estimated using Cox 
proportional hazard models18 with Efron’s approximation for tied event times.19 Wald-type 
95% confidence intervals were estimated using the standard large-sample variance 
approximation in the crude and regression adjusted models, and robust variance for weighted 
models.20 The proportional hazards assumption was assessed visually from the plot of the 
non-parametric estimates of the log cumulative hazard functions.
As requirements for Medicaid eligibility are based on income, inclusion of income as a 
confounder violates the positivity assumption (i.e., there are few high income participants on 
Medicaid; see Supplemental Figure 1).21 A common solution to positivity violations is to 
restrict analysis to a subset in which there is positivity. Therefore, to estimate the effect of 
income on unsuppressed HIV viral load, we restricted this analysis to participants who were 
on Medicaid at visit 24.
Observed data were weighted by the product of stabilized inverse probability-of-exposure-
and-censoring weights to account for confounding and selection bias by measured 
characteristics.22,23 This method, conditional on a few assumptions, approximates a 
randomized trial by reweighting the population so that health insurance is randomly 
distributed conditional on confounders included in the weight estimation model.24 Health 
insurance type was modeled using standard multinomial logistic models; censoring was 
modeled using pooled logistic regression. Confounders included age (using restricted 
quadratic splines (RQS)25 with knots at 35.7, 41.6, 46.7, and 50.8 years), African American 
race, study site, lowest observed CD4 cell count (using RQS with knots at 94, 191, 269, and 
383 cells/µL), prior HIV viral load (as the average of the log10 viral load for 3 visits prior to 
the index date, using RQS with knots at 4.4, 4.7, 7.4, and 9.7), and prior health insurance 
status (6 months prior). Not included as confounders in the final weight model were 
recruitment wave, Hispanic ethnicity, and prior AIDS diagnosis as these variables did not 
alter the variance or final effect estimate. A trial in which health insurance is randomized 
would have randomized on prior viral load, and therefore we included prior viral load as a 
potential confounder. However, due to concern about over-adjustment, we present results 
that do and do not account for prior viral load. Weights were stabilized by prior health 
insurance type. The resultant weights had a mean (standard deviation (SD)) of 1.10 (2.46) 
with a range of 0.003 to 86.24. Inverse probability of exposure weights trimmed at 0.1 and 
Ludema et al. Page 4
J Acquir Immune Defic Syndr. Author manuscript; available in PMC 2017 November 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
10 yielded weights with a mean (SD) of 1.03 (0.90). Results using the trimmed weights are 
reported here23; use of untrimmed weights produced similar results.
Income was modeled in a similar fashion using multinomial logistic regression; censoring 
was modeled using pooled logistic regression. Candidate confounders included age, African 
American race, study site, nadir CD4 cell count, and prior viral load. Similar to the analysis 
of health insurance, we present results that do and do not account for prior viral load. The 
resultant weights had a mean (SD) of 0.99 (0.36) with a range of 0.15 to 4.48. All analyses 
were conducted using SAS 9.3 (SAS Institute, Cary, North Carolina).
RESULTS
Among 1,481 HIV-infected WIHS women, most (65%) reported Medicaid as their insurance 
provider, 18% had private insurance, 3% had Medicare or other public insurance, and 14% 
reported no health insurance (Table 1). Over the three year study period, 15% of participants 
reported a change in insurance type subsequent to the index date. Changes in insurance (loss 
or gain) were not differentially distributed by unsuppressed viral load.
The median age of participants with other public insurance (median; interquartile range 
(IQR): 38; 33, 46) was lower than those on Medicaid (median; IQR: 43; 38, 49). African 
Americans comprised 56% of the population; of the 963 participants on Medicaid, 62% 
were African American. Hispanics comprised 27% of the overall population, and 
represented 45% of the uninsured. The distribution of insurance type by WIHS site varied; 
45% of the participants on Medicaid attended a site in New York. Half of the participants 
with other insurance attended a site in California. Participants with Medicaid were the most 
likely to have a yearly income of less than $12,000 a year (62%, for full distribution see 
Supplemental Materials), were less likely to be employed (21%), and fewer attained a high 
school education (45%) compared with other groups. While women with Medicaid group 
reported more prior AIDS diagnoses (46%), the median lowest observed CD4 cell count 
among all groups was similar.
About three quarters of the total population was using ART at the index visit. There were no 
differences in ART use by health insurance category. Women with no health insurance 
(56%) and those with other public insurance (31%) were more likely to participate in ADAP 
than those with private insurance (17%) or Medicaid (11%).
There were 898 women who had viral load measurements >200 copies/mL over the 4,917 
visits that occurred during 2006–2009. The median time to first unsuppressed viral load was 
525 days (IQR: 189, 1082) with a median unsuppressed viral load of 3,400 copies/mL (IQR: 
710, 23,000). In the crude analysis, participants with Medicaid without ADAP (the referent 
group) had the highest hazard of a viral load >200 copies/mL (Table 2).
Weighted analyses are presented in Table 2. Weights for other insurance were not estimated 
because this group was a conglomeration of types of insurance with substantially different 
eligibility criteria. These weighted results represent marginal estimates, in this case the 
hazard ratio of virologic failure if all participants in the study received a given exposure 
compared to if all participants received the referent exposure (i.e., Medicaid without ADAP). 
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In models which account for study site, age, race, lowest CD4 cell count, and prior HIV viral 
load, ADAP only (HR: 0.49, 95% CI: 0.28, 0.85), private insurance without ADAP (HR: 
0.61, 95% CI: 0.48, 0.77), and private insurance with ADAP (HR: 0.52 95% CI: 0.31, 0.91) 
all had lower hazards of virologic failure compared to Medicaid without ADAP.
Among participants on Medicaid, a yearly income of >$18,000 per year compared to <
$6,000/year, yielded a hazard ratio of 0.79 (95% CI: 0.60, 1.02) when accounting for study 
site, age, race, and lowest CD4 cell count (Table 3). When we additionally accounted for 
prior viral load, the hazard ratio comparing these same groups moved to 1.06 (95% CI: 0.80, 
1.41).
DISCUSSION
We evaluated the effect of health insurance status and type on risk of having an 
unsuppressed HIV viral load among HIV-infected women in the WIHS over the span of 
three years. Among participants who did not participate in ADAP, those with Medicaid or no 
insurance were most likely to have unsuppressed viral load compared to women with private 
insurance. Among HIV-infected women in all insurance categories except private insurance, 
ADAP increased the likelihood of virologic suppression, especially among otherwise 
uninsured women, who were twice as likely to achieve virologic suppression if on ADAP. 
These findings underscore the importance of this program.
In addition to antiretroviral medications, participants enrolled in ADAP may have accessed 
case management, patient transportation, and child-care during HIV-related appointments. 
Availability of these auxiliary programs may explain a portion of the beneficial effects of 
ADAP observed in this study.
Health insurance is likely to impact all steps along the HIV continuum of care: HIV 
diagnosis, linkage to care, retention in care, prescription of ART, and viral suppression. For 
example, in a cross-sectional analysis among WIHS women eligible for ART, ADAP 
participation was associated with increased use of ART.26 Additionally, people living in 
states that did not contribute to the ADAP budget were more likely to have delayed initiation 
of ART after treatment was indicated.27 Further along the continuum of care, McFall et al. 
showed that among white and Hispanic women on ART in the WIHS, lack of health 
insurance (compared with public health insurance) was associated with virologic failure 
following suppression.28 These studies suggest that type and status of health insurance 
influence ART receipt and virologic failure after suppression. However, because health 
insurance strongly affects the likelihood that an individual will receive ART, the effect of 
health insurance on virologic suppression in a population with diverse health insurance 
coverage cannot be extrapolated only from participants who are on ART. The current study 
provides estimates of the effects of health insurance that include the pathway through access 
to ART, and thus evaluates the effect of health insurance on viral suppression in a study 
population that more closely approximates the general population of HIV-infected women in 
the US.
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Poverty increases mortality among HIV-infected people,29,30 but the pathways between 
poverty and death are not well established. In our study population, even among women with 
Medicaid (who by virtue of their Medicaid eligibility already have low income), those in the 
lowest income category were less likely to experience viral suppression even after 
adjustment for nadir CD4 cell count. Although initial viral load can affect future virologic 
response, adjustment for viral load prior to study entry could inappropriately nullify the 
relationship between income and subsequent virologic suppression: high income individuals 
with high initial viral loads likely have greater resources and ability to navigate complex 
care systems than those with much lower incomes.
This study has some limitations. First, participants may not have correctly self-reported their 
health insurance (status and type) and their incomes. Though we have no available 
confirmatory data on health insurance during this study period, we did compare current 
report of health insurance with clinic records among Chapel Hill WIHS participants. Among 
this group (n=67), 94% of self-reported insurance type matched the insurance type on file at 
the clinic (data not shown). In addition, studies have suggested31–33 that those who self-
reported no insurance are likely uninsured, and that there are few participants who self-
reported Medicaid insurance when they were privately insured. Second, as in all 
observational studies, we rely on the assumption of no unmeasured confounding. For the 
relationship between health insurance and viral load suppression, an important confounder, 
income, was not accounted for. We were unable to account for this confounder because of 
positivity (i.e., no high income participants in Medicaid). Third, participants in the WIHS, a 
long-term cohort study in states with generous ADAP programs (see Supplemental 
Materials), may differ from the HIV-infected population in the US, limiting generalizability. 
Finally, we assume that the variations within types of insurance coverage were negligible 
with regards to viral load suppression (i.e., consistency). However, not all types of insurance 
coverage are homogeneous, and participants may have had different levels of coverage and 
services that likely had an impact on viral load suppression.34 By adjusting for study site, we 
accounted for some of this variability between Medicaid plans as this type of insurance 
coverages is determined by the state.
In conclusion, our results underscore the importance of health insurance and ADAP 
coverage in suppression of HIV viral load. Suppression of viral load on the individual level 
has been identified as a crucial piece in HIV transmission,9,10 and consequently impacts the 
public’s health. A number of factors, including high comorbidities, inadequate access to 
health resources, and substance use contribute to the poor outcomes for those with 
Medicaid35 and should not be interpreted as dissuasion to expand Medicaid coverage. 
Increasing provision of insurance to HIV-infected people will likely increase the proportion 
of virally suppressed individuals. However, not all states have expanded Medicaid coverage, 
leaving a gap in health care access for the working poor.36 Participation in ADAP improves 
HIV outcomes; this program may be especially critical for HIV-infected people in states that 
have not expanded Medicaid.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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